ALLEN WAYNE MANGEL, M.D., Ph.D.

*** ********* *****

Chapel Hill, NC 27514

Home Phone: 919-***-****

Cell Phone: 919-***-****

email: adw5mi@r.postjobfree.com

EDUCATION

DUKE UNIVERSITY MEDICAL CENTER, Durham, NC (1988-1993) Fellow in Gastroenterology

Senior Assistant Resident in Medicine

Junior Assistant Resident in Medicine

Intern in Medicine

Awards and Honors:

• The National Institute of Diabetes and Digestive and Kidney Diseases Medical Resident Award

• National Research Service Award

• Glaxo Institute for Digestive Health Basic Science Award GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE, Washington, DC

(1984-1988)

M.D.

Awards and Honors:

• Alpha Omega Alpha

• Upjohn Achievement Award for Academic Research

• Sandoz Research Award

UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, Miami, FL (1980-1982) Postdoctoral Fellow, Department of Pharmacology,

Awards and Honors:

Awarded American Heart Association (Florida Affiliate) Post-doctoral Fellowship EDUCATION (continued)

UNIVERSITY OF ILLINOIS, Urbana, IL (1971-1980)

Ph.D. (Physiology): Thesis: Effects of Alterations in Calcium Levels on Cat Small Intestinal Slow Waves.

M.S. (Physiology): Thesis: Effects of Metabolic Correlates on Cat Small Intestinal Slow Waves.

B.S. (Physiology)

Awards and Honors:

• Edmund J. James Scholar

• Phi Eta Sigma

• Sigma Xi

PROFESSIONAL EXPERIENCE

RESEARCH TRIANGLE INSTITUTE:

I. RTI HEALTH SOLUTIONS (Business Unit), 2003—May 2023 Executive Vice-President 2009-May 2023

Senior Vice-President 2007-2009

Vice-President 2004-2007

Global Head of Medical Services 2003-2004

Responsibilities: As leader of Health Solutions all seven research groups:

---health economics,

---patient reported outcomes,

---epidemiology,

---market access and outcomes strategy,

---survey and observational studies,

---biostatistics and

---health preference assessment,

as well as support functions (finance, contracts, quality assurance, proposal office, editors, business development), ultimately reported up to me. In leading Health Solutions I served as an officer of RTI International. Relevant Regulatory/Clinical Development Experience:

---Special Government Employee (Two Terms): Role:

Voting consultant on FDA Gastrointestinal Drug Advisory Committee

---FDA Advisory Committee Presentations

---Label negotiations with FDA

---Active participant in construction of NDAs

---Pre-NDA, End of Phase 2, Pre-IND meetings with FDA

---Meetings with Japanese Regulatory Agency

---Consultant Chief Medical Officer

---Numerous presentations to various venture capital groups to raise funds for client companies

---Participation in numerous Phase 2,3,4 clinical trials

---Participation on Drug Safety Monitoring Boards (DSMBs) II. DISCOVERY SCIENCES (Business Unit), 2018—May 2023 Executive Vice-President, 2018-Present

Responsibilities: In addition to leading the Health Solutions business unit, I led Discovery Sciences business unit comprised of three research groups:

--Chemistry and Pharmacology

--Analytical Sciences

--Analytical Chemistry

III. RTI INTERNATIONAL, 2019—May 2023

Chief Medical Officer

IV. OVERALL

In Health Solutions there are approximately 380 staff members with offices located in 5 countries. When I began leading Health Solutions in 2006, there were about 40 staff members.

In Discovery Sciences there are approximately 150 staff members. QUINTILES, 2001

Durham, NC

Director of Regulatory Affairs

SALIX PHARMACEUTICALS, 2001-2003

Raleigh, NC

Vice President, Research and Development 2001-2003 PROFESSIONAL EXPERIENCE (continued)

GLAXOWELLCOME/GLAXOSMITHKLINE, 1995-2001

Research Triangle Park, NC

GSK: Head, Gastroenterology Clinical Development 2001 GW: International Therapeutic Director, Gastroenterology 1998-2001 GW: Director of Gastroenterology Clinical Research 1997-1998 GW: Senior Clinical Research Physician/Associate Director of Gastroenterology Clinical Research 1995-1997

DUKE UNIVERSITY MEDICAL CENTER, 1993-1995,

Durham, NC

Assistant Professor of Medicine (Gastroenterology) 1994-1995 Associate in Medicine (Gastroenterology) 1993-1994 MERCK SHARP AND DOHME RESEARCH LABORATORIES, 1982-1984 West Point, PA

Senior Research Pharmacologist1982-1984

Division of Gastroenterology

PUBLICATIONS

I. JOURNAL ARTICLES: MAJOR PAPERS

1. Allen W. Mangel, D.O. Nelson, John A. Connor and C.L. Prosser (1979) Contractions of cat small intestinal smooth muscle in calcium free solution. Nature 281: 582-583.

2. John A. Connor, Allen W. Mangel and Burr Nelson (1979) Propagation and entrainment of slow waves in cat small intestine. Am. J. Physiol. 237: C237-246.

3. Allen Mangel and C. Ladd Prosser (1980) Rhythmic electrical activity in stomach and intestine of toad. J. Exp. Biol. 86: 237-248. 4. Allen Mangel, Mohammad Fahim and Cornelis van Breemen (1981) Rhythmic contractile activity of the in vivo rabbit aorta. Nature 289: 692-694.

5. Allen Mangel, John Connor and C. Ladd Prosser (1982) The effects of alterations in calcium levels on cat small intestinal slow waves. Am. J. Physiol. 243: C7-13.

6. Cornelis van Breemen, Allen Mangel, Mohammad Fahim and Kaushik Meisheri (1982) Selectivity of calcium antagonistic action in vascular smooth muscle. Am. J. Cardiol. 49: 507-510.

7. Allen Mangel, Mohammad Fahim, and Cornelis van Breemen (1982) Control of vascular contractility by the cardiac pacemaker. Science 215: 1627- 1629.

8. Allen Mangel, D.O. Nelson, Joel L. Rabovsky, C. Ladd Prosser and John A. Connor (1982) Depolarization induced contractile activity of smooth muscle in calcium free solution. Am. J. Physiol. 242: C36-40. 9. Allen W. Mangel and Andrea Koegel (1984) The effects of peptides on gastric emptying. Am. J. Physiol. 246: G342-345.

10. M. Williams, G. Martin, D. Remy, M. Hichen, A. Mangel, D. Taylor, G. Yarbrough, R. Bendesky, S. King, J. Robinson, J. Totaro and B. Clineschmidt (1984) L-646,462, a cycloheptadine related antagonist of dopamine and serotonin with selectivity for peripheral systems. J. Pharm. Exp. Ther. 229: 775-781.

11. Robert G. Pendleton, Patricia G. Cook, Alene Shepherd-Rose and Allen W. Mangel (1985) Effects of H2-receptor antagonists upon physiological acid secretory states in animals. J. Pharm. Exp. Ther. 233: 64-69. 12. Richard A. Gillis, Jannette Dias Souza, Karen A. Hicks, Allen W. Mangel, Frank D. Pagania, Betty Hamilton, Thomas Q. Garvey III, Daniel G. Pace, Ronald K. Browne and Wesley P. Norman (1987) Inhibitory control of proximal colonic motility by the sympathetic nervous system. Am. J. Physiol. 253: G531-539.

13. Allen W. Mangel, J. Gregory Fitz and Ian L. Taylor (1991) Modulation of rabbit colonic motility by substance-P, cholecystokinin and neuropeptide- Y. Peptides 12: 1063-1067.

14. Allen W. Mangel and Ian L. Taylor (1992) Modulation of electrical activity in gastrointestinal smooth muscle by peptides. Regulatory Peptides 42: 1-13.

.

15. Allen W. Mangel, John R. Raymond and J. Gregory Fitz (1993) Regulation of high conductance anion channels by G proteins and 5-HT1A receptors in CHO cells. Am. J. Physiol. 264: F490-495.

16. Allen W. Mangel, Nicholas D. Snow, Mary Ann Misukonus, Srisaila Basavappa, John P. Middleton, J. Gregory Fitz and Rodger A. Liddle

(1993) Calcium-dependent regulation of cholecystokinin secretion and potassium currents in STC-1 cells. Am. J. Physiol. 264: G1031-1036. 17. T.S. Steiner, A.W. Mangel, D.C. McVey and S.R. Vigna (1993) Secretin receptors mediating rat forestomach relaxation. Am. J. Physiol. 264: G863- 867.

18. John P. Middleton, Allen W. Mangel, Srisaila Basavappa and J. Gregory Fitz

(1993) Nucleotide receptors regulate membrane ion transport in renal epithelial cells. Am. J. Physiol. 264: F867-873.

19. Srisaila Basavappa, John P. Middleton, Allen W. Mangel, James M. McGill, Jonathon Cohn and J. Gregory Fitz (1993) Chloride transport in human biliary cell lines. Gastroenterology. 104: 1796-1805. 20. Allen W. Mangel, Veronica Prpic, Nicholas D. Snow, Srisaila Basavappa, Lainie J. Hurst, Ala I. Sharara and Rodger A. Liddle (1994) Regulation of cholecystokinin secretion by ATP-sensitive potassium channels. Am. J. Physiol. 267: G595-600.

21. Nicholas D. Snow, Veronica Prpic, Allen W. Mangel, Douglas C. McVey, Ala I. Sharara, Lainie J. Hurst, Steven R. Vigna and Rodger A. Liddle (1994) Bombesin-regulated secretion of CCK in STC-1 cells. Am. J. Physiol. 267: G859-865.

22. J.M. McGill, S. Basavappa, A.W. Mangel, G.H. Shimokura, J.P. Middleton and J.G. Fitz (1994) ATP activates ion permeabilities in biliary epithelial cells. Gastroenterology. 107: 236-243.

23. Allen W. Mangel, Veronica Prpic, Helen Wong, Lainie J. Hurst, Srisaila Basavappa, LeAnn Scott, Robert L. Garman, Jasmine S. Hayes, Ala I. Sharara, Nicholas D. Snow, John H. Walsh and Rodger A. Liddle (1995) Phenylalanine stimulated secretion of cholecystokinin is calcium dependent. Am. J. Physiol. 268: G90-94.

24. Srisaila Basavappa, Vanessa Charttouni, Kiaran Kirk, Veronica Prpic, J. Clive Ellory, and Allen W. Mangel (1995) Swelling-induced chloride currents in neuroblastoma cells are calcium-dependent. J. Neuroscience 15: 3662-3666.

25. Allen W. Mangel (1995) Electrophysiology of cholecystokinin secretion. Regulatory Peptides 56: 121-129.

26. Allen W. Mangel, LeAnn Scott, and Rodger A. Liddle (1996) Depolarization stimulated cholecystokinin secretion is mediated by L-type calcium channels in STC-1 cells. Am. J. Physiol. 270: G287-290.

27. LeAnn Scott, Veronica Prpic, William D. Capel, Srisaila Basavappa, Allen W. Mangel, Thomas W. Gettys, and Rodger A. Liddle (1996) Beta- adrenergic regulation of cholecystokinin secretion in STC-1 cells. Am. J. Physiol. 270: G291-297.

28. Allen W. Mangel, LeAnn Scott, Veronica Prpic, and Rodger A. Liddle (1996) Regulation of cholecystokinin secretion in STC-1 cells by nitric oxide. Am. J. Physiol. 271: G650-654.

29. Srisaila Basavappa, Chium-Chien Huang, Allen W. Mangel, Dmitry V. Lebedev, Philip A. Knauf, and J. Clive Ellory (1996) Swelling-activated amino acid efflux in the human neuroblastoma cell line CHP-100. J. Neurophysiol. 76: 764-769.

30. J.P. Harding, L.R. Hamm, R.S.B. Ehsanullah, A.T. Heath, S.C. Sorrells, J. Haw,G.E. Dukes, S.G. Wolfe, A.W. Mangel, and A.R. Northcutt (1997) Use of a novel electronic data collection system in multicenter trials of irritable bowel syndrome. Aliment. Pharm. Ther. 11: 1073-1076. 31. A.W. Mangel, B.A. Hahn, A.T. Heath, A.R. Northcutt, S. Kong, G.E. Dukes and D. McSorley (1998) Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J. Int. Med. Res. 26: 76-81. 32. Michael Camilleri, Emeran A. Mayer, Douglas A. Drossman, Amy T. Heath,George E. Dukes, David McSorley, Steven Kong, Allen W. Mangel and Allison R. Northcutt (1999) Treatment of female irritable bowel syndrome patients with alosetron, a 5HT3-receptor antagonist. Aliment. Pharm. Ther. 13: 1149-1159.

33. Masatake Miura, D. Curtis Lawson, Allen W. Mangel and Theodore N. Pappas (1999) Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5HT3 receptor antagonist. Dig. Dis. Sci. 44: 20-24.

34. Allen W. Mangel and Allison R. Northcutt (1999) Review Article: safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients. Aliment. Pharm. Ther. 13 (Suppl 2) 77-82. 35. Theodore N. Pappas, Allen W. Mangel and Curtis Lawson (1999) Alosetron: central and peripheral effects in an animal model of gut distension. Aliment. Pharm. Ther. 13 (Suppl. 2) 54-6.

36. Lynne R. Hamm, Susan C. Sorrells, Jacqueline P. Harding, Allison R. Northcutt Amy T. Heath, Gordon F. Kapke, Chrisitne M. Hunt and Allen W. Mangel (1999) Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome Criteria. Am. J. Gastroent. 94: 1279-82.

37. M. Camilleri, A.R. Northcutt, S. Kong, G.E. Dukes, D. McSorley and A.W. Mangel (2000) The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomized, placebo controlled trial. The Lancet 335: 1035-1040.

38. J.K.L. Walker, R.R. Gainetdinov, A.W. Mangel, M.G. Caron and M.A. Shetzline (2000) Mice lacking the dopamine transporter display altered regulation of distal colonic motility. Am. J. Physiol. 279: G311-318.52. 39. M. Camilleri, W. Y. Chey, E.A. Mayer, A.R. Northcutt, A. Heath, G.E. Dukes, D. McSorley and A.W. Mangel (2001) Alosetron relieves abdominal pain, and improves abnormal bowel function in female, non-constipated, irritable bowel syndrome patients. Arch. Int. Med. 161: 1733-1740. 40. M. Watson, L. Lacy, S. Kong, A. Northcutt, D. McSorley, B. Hahn, and A. Mangel (2001) Alosetron improves quality of life in women with diarrhea- predominant irritable bowel syndrome. Am. J. Gastroent. 96: 455-459. 41. N. J. Talley, S. V. van Zanten, G. Dukes, T. Perschy, M. Heath, C. Kleoudis, and A.W. Mangel (2001) A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment. Pharm. Ther. 15: 525-537.

42. E.B. Andrews, S.C. Eaton, K.A. Hollis, J.S. Hopkins, V. Ameen, L.R. Hamm, S.F. Cook, P. Tennis, A.W. Mangel (2005) Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment. Pharm. Ther. 22: 935-942..

43. Rachel E. Williams, Carla L. Black, Hae-young Kim, Elizabeth B. Andrews, Allen W. Mangel, Jeff J. Buda and Suzanne F. Cook (2006). Stability of irritable bowel syndrome (IBS) using a Rome II-based classification. Aliment. Pharm. Ther. 23: 197-205.

44. R.E. Wiiliams, C.L. Black, H.-Y. Kim, E.B. Andrews, A.W. Mangel, J.J. Buda and S.F. Cook (2006) Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment. Pharm. Ther. 23: 1667-1675.

45. Michael Camilleri, Allen W. Mangel, Douglas A. Drossman, Sheri Fehnel, Emeran A. Mayer and Nicholas J. Talley (2007) Primary endpoints for IBS trials: a review of psychometrics and performance of endpoints. Clinical Gastro and Hepatology. 5: 534-540.

46. S. M. Leventer, K. Raudibaugh, C.L. Frissora, N. Kassem, J.C. Keogh, J. Phillips and A.W. Mangel (2008) Clinical Trial: Dextofisopam in the treatment of patients with diarrhea-predominant or alternating irritable bowel syndrome. Aliment. Pharm Ther. 27: 197-206.

47. A.W. Mangel, J.D. Bornstein, L.R. Hamm, J. Buda, J. Wang, W. Irish, D. Urso (2008) Clinical Trial: Asimadoline in the treatment of IBS. Aliment. Pharm. Ther. 28: 239-249.

48. Suzanne F. Cook, Lee Lanza, Xiaolei Zhou, Carolyn T. Sweeney, Diana Goss, Kelly Hollis, Allen W. Mangel, and Sheri E. Fehnel (2008) Characteristics, demographics, and gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment. Pharm. Ther. 27,1224-1232.

49. Allen W. Mangel and Sheri E. Fehnel (2008) Design of treatment trials in irritable bowel syndrome: opioid agonists and atypical benzodiazepine antagonists. Neurogastroenterology and Motility. 20: 1086-1093. 50. Allen W. Mangel and Pravin Chaturvedi (2008) Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome (D-IBS) patients.Digestion. 78: 180-186.

51. Brennan Spiegel, Michael Camilleri, Roger Bolus, Viola Andresen, William Chey, Sheri Fehnel, Allen Mangel, Nicholas J. Talley, and William E. Whitehead (2009) Psychometric evaluation of endpoints in IBS randomized controlled trials. Gastroenterology. 137: 1944-1953.

.

52. M. Goldberg, J. Johanson, A.W. Mangel, Y.-P. Li, M. Kitt, D.T. Beattie and O. Daniels (2010) Efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation: a four- week, randomized, double-blind, placebo-controlled dose-response study. Aliment. Pharm. Ther. 32: 1102-1112.

53. Allen W. bMangel and Valerie S.L. Williams (2010) Asimadoline in the treatment of irritable bowel syndrome. Expert Opinion on Investigational Drugs. 19: 1257-64

54. Jianmin Wang, Beth Sherril, Lynne R. Hamm and Allen W. Mangel (2010) Does timing of endoscopic procedures affect outcomes in IBS trials? Gastroenterology Research. 3: 185-90.

55. Emily D. Evans and Allen W. Mangel (2011) Review: Depolarization- stimulated contractility of gastrointestinal smooth muscle in calcium-free solution. ISRN Gastroenterology. Vol 2011 Article ID 692528. doi: 10.5402/2011/692528.

56. Allen W. Mangel, Jianmin Wang, Elizabeth Sherrill, Ari Gnanasakthy, Claire Ervin and Sheri E. Fehnel (2011) Urgency as an endpoint in irritable bowel syndrome. Gastroenterology Research 4: 9-12. 57. Allen W. Mangel and Sheri E. Fehnel (2011) Endpoints in irritable bowel syndrome. Expert Reviews in Gastroenterology and Hepatology.5: 293-295. 58. Allen W. Mangel and Gareth Hicks (2012) Asimadoline and its potential for the treatment of diarrhea predominant irritable bowel syndrome: a review. Clinical and Experimental Gastroenterology 5: 1-10. 59. Claire M. Ervin and Allen W. Mangel (2013) Clinical trials in irritable syndrome: a review. Reviews on Recent Clinical Trials. 8: 9-22. 60. Allen W. Mangel (2013) What should be the primary endpoint in irritable bowel syndrome? Clinical Investigation 3: 131-136. 61. Claire M. Ervin, Sheri E. Fehnel, Mollie Baird, Robyn Carson, Jeffrey M. Johnston, Steven J. shiff, Caroline B. Kurtz, and Allen W. Mangel (2014) Assessment of treatment responses in chronic constipation clinical trials. Clinical and Experimental Gastroenterology. 7: 191-198. 62. Sarah B. Marion and Allen W. Mangel (2014) From depolarization-dependent contractions in gastrointestinal smooth muscle to aortic pulse synchronized contractions. Clinical and Experimental Gastroenterology. 7:61-66. 63. Allen W. Mangel (2014) Does the aortic smooth muscle wall undergo rhythmic contractions during the cardiac cycle? Experimental and Clinical Cardiology. 20: 6844-6851.

64. Niaz Sahibzada, Allen W. Mangel, Jaclyn E. Tatge, Kenneth Dretchen, Michael R. Franz, Renu Virmani and Richard A. Gillis (2015) Rhythmic aortic contractions induced by electrical stimulation in vivo. PLoS One 10(7):e0130255.doi: 10:1371.

65. Susan Boklage, Allen W. Mangel, Varun Ramamohan, Deirdre Mladsi and Tao Wang (2016) Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Preference and Adherence. 10: 45-55. 66. Susan Boklage, Allen W. Mangel, Varun Ramamohan, Deidre Mladsi and Tao Wang (2016) Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Preference and Adherence. 10: 1025-1035.

67. Allen W. Mangel (2017) A changing paradigm for understanding the behavior of the cardiovascular system. Journal of Clinical & Experimental Cardiology. 8: 496.doi:10.4172/2155-9880.1000496.

68. A. Mangel and K. Lothman (2017) Emergence of a new paradigm in understabnding the cardiovascular system: pulse synchronized contractions. Cardiovascular Pharmacology 6 (5): 220. DOI: 10:4172/2329-6607.1000220. 69. Allen W. Mangel and Kate Lothman (2018) Pulse synchronized contractions

(PSCs): a call to action. Open Journhal Cardiology and Heart Disease 1(2) OJCHD.000508.

70. Allen W. Mangel, Katherine Lothman and Tobin P. Mangel (2020) Pulse Synchronized Contractions: A Review. EC Cardiology 7(8): 61-66 71. Tobin P. Mangel, Katherine Lothman and Allen W. Mangel (2021) Pulse Synchronized Contractions (PSCs): An Invited Review. EC Cardiology 8(4) 18-21.

72. Carla Romano, Sheri Fehnel, Jeffrey Stoddard, Jerald Sadoff, Sandy Lewis, Pauline McNulty, Eric K H Chan, Emily Evans, Carol Jamieson, Ashley F Slagle, Allen Mangel and Kelly McQuarrie (2022) Development of a Novel Patient- Reported Outcome Measure to Assess Signs and Symptoms of Covid-19. J. of Patient-Reported Outcomes 29; 6, 85.

II. SHORT COMMUNICATIONS/LETTERS TO THE EDITORS/EDITORIALS 73. Allen W. Mangel and D.O. Nelson (1978) EGTA induced fast potentials in rat small intestine. Life Sciences 22: 647-650.

74. Allen W. Mangel and D.O. Nelson (1978) Slow-waves in rat small intestine. Life Sciences 23: 1139-1142.

75. Allen Mangel and Cornelis van Breemen (1981) Rhythmic electrical activity in rabbit aorta induced by EGTA. J. Exp. Biol. 90: 339-342. 76. Mohammad Fahim, Allen Mangel, and Berton Pressman (1983) Effect of ionophore-mediated sodium transport on the cardiac resting potential. J. Exp. Biol. 107: 491-493.

77. Allen W. Mangel, John R. Stavorski and Robert G. Pendleton (1983) Effects of bethanechol, metoclopramide and domperidone on antral contractions in cats and dogs. Digestion 28: 205-209.

78. Allen W. Mangel (1984) Potentiation of colonic motility to CCK and other peptides. Eur. J. Pharm. 100: 285-290.

79. Allen Mangel (1984) Voltage and receptor mediated contractile activity of colonic smooth muscle in calcium free solution. Eur. J. Pharm. 102: 165-168.

80. D.O. Nelson, A.W. Mangel, C.A. Graham, J.W. Frederiksen, E.J. Green, L.J. Segil and C.P. Mangel (1984) Altered human vascular activity following withdrawal from calcium channel blockers. J. Cardio. Pharm. 6: 1249-1250. 81. Allen W. Mangel (1987) Cholinergically mediated exaggeration of the colonic motor response to cholecystokinin. Am. J. Gastroent. 82: 174-175. 82. Allen W. Mangel, Kenton M. Sanders, David Jevsevar, Robert J. Gould, Stuart V. Pineo, Sylvia Wiese and Richard A. Gillis (1989) Exaggeration of the cholecystokinin-induced motor response in the cat gastrointestinal tract. Digestion 43: 196-203.

83. Allen Mangel (1989) Pulse synchronized contractions: an addendum to Windkessel. Am. J. Physiol. 256: H928.

84. Allen W. Mangel, Scott R. Brazer, Judy W. Smith, J. Gregory Fitz and Ian L. Taylor (1992) Inhibition of colonic motility by cholecystokinin. Ann. Med. 24: 341-342.

85. Allen W. Mangel, Srisaila Basavappa, John R. Raymond and J. Gregory Fitz

(1992) cAMP-regulated chloride currents in CHO cells. Bioch. Bioph. Res. Comm. 186: 251-255

86. Nicholas D. Snow, Allen W. Mangel, Ala I. Sharara and Rodger A. Liddle

(1993) Potassium channels regulate cholecystokinin secretion in STC-1 cells. Bioch. Bioph. Res. Comm. 195: 1379-1385.

87. Allen W. Mangel, Veronica Prpic, LeAnn Scott and Rodger A. Liddle (1994) Inhibitors of ATP-sensitive potassium channels stimulate intestinal cholecystokinin secretion. Peptides 15: 1565-1566. 88. Veronica Prpic, Srisaila Basavappa, Rodger A. Liddle, and Allen W. Mangel

(1994) Regulation of cholecystokinin secretion by calcium-dependent calmodulin kinase II: differential effects of phenylalanine and cAMP. Bioch. Bioph. Res. Comm. 201: 1483-1489.

89. Srisaila Basavappa, Rodger A. Liddle and Allen W. Mangel (1994) Characterization of ATP-sensitive potassium channels in an intestinal, cholecystokinin secreting cell. Bioch. Bioph. Res. Comm. 204: 855-860. 90. Srisaila Basavappa, Marco A. Romano-Silva, Allen W. Mangel, Diago Laro, Iain Campbell and Michael Brammer (1994) Inhibition of K channel activity by 4-APstimulates N-type Ca channels in CHP-100 cells. Neuroreports 5: 1256-1258.

91. James M. McGill, Margaret S. Yen, Srisaila Basavappa, Allen W. Mangel, and Ann P. Kwiatkowski (1995) ATP-activated chloride permeability in biliary epithelial cells is regulated by calmodulin-dependent protein kinase II. Bioch. Bioph. Res. Comm. 208: 457-462.

92. Allen W. Mangel (1997) Management of gallbladder polyps. Southern Medical Journal. 90: 481-483.

93. S. Basavappa, A.W. Mangel, L.Scott and R.A. Liddle (1999) Activation of calcium channels by cAMP is dependent upon Ca+2 calmodulin-dependent protein kinase II. Bioch. Bioph. Res. Comm. 254: 699-702. 94. Allen W. Mangel (2000) Alosetron in irritable bowel syndrome. The Lancet 356: 164-165.

95. Allen W. Mangel (2000) Alosetron in irritable bowel syndrome. The Lancet 356: 2009-2010.

96. S. Basavappa, A.W. Mangel and E.L. Boulpaep (2003) Calcium-dependent, swelling-activated K+ conductance in human neuroblastoma cells. Biochem Biophys Res Comm. 308: 759-763.

97. Allen W. Mangel (2004) Study design issues in irritable bowel syndrome. Aliment. Pharm. and Ther. 19:141-142.

98. Allen W. Mangel (2005) Post-infectious IBS. Am. J. Gastroent. 100: 729. 99. Allen W. Mangel and Sheri E. Fehnel (2005) Global endpoints in functional gastrointestinal disease. Aliment. Pharm. and Ther.. 22: 1162-1163. 100. Allen W. Mangel and Sheri E. Fehnel (2006) Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am. J. Gastroent. 101: 2884-2885

101. Allen W. Mangel (2006) Adequate relief as a primary endpoint in irritable bowel syndrome. Aliment. Pharm. Ther. 23: 879-881. 102. Allen W. Mangel (2009) The FDA and IBS drug development. Am. J. Gastroent. 104: 310.

103. Mangel AW, Johanson J, Lu YP, Kersey K, and Daniels O. (2011) Defining a responder in treatment trials for chronic idiopathic constipation. Aliment Pharm Ther 33:286-7.

104. TP Mangel, K Lothman and AW Mangel (2022) A proposed physiologic role for pulse synchronized contractions (PSCs): Expert Opinion. Cardiology and Vascular Research 6(3): 1.

III. BOOK CHAPTERS, SYMPOSIA VOLUMES, NON-REFEREED ARTICLES 105. D.O. Nelson and A.W. Mangel (1979) Acetylcholine induced slow-waves in cat esophageal smooth muscle. Gen. Pharmacol. 10: 19-21. 106. D.O Nelson and A.W. Mangel (1979) Napthalene-induced crayfish muscle membrane hyperpolarization. Comp. Bioch. Physiol. 63C: 309-311. 107. C. van Breeman, R. Loutzenhiser, A. Mangel, and K. Meisheri (1980) Calcium compartments in vascular smooth muscle. In: Advances in Physiological Sciences vol. 5 Molecular and Cellular Aspects of Muscle Function. ed. E. Varga, A. Kover, T. Kovacs, and L. Kovacs. Pergamon Press. Budapest. pp. 47-53.

108. C. Ladd Prosser and Allen W. Mangel (1982) Mechanisms of spike and slow wave pacemaker activity in smooth muscle cells. In: Cellular Pacemakers. vol. 1. ed. D. Carpenter. John Wiley and Sons. N.Y. pp. 273- 301.

109. Cornelis van Breemen, Phillip I. Aaronson, Cynthia A. Cauvin, Rodger D. Loutzenhiser, Allen W. Mangel and Kooichi Saida (1982) The calcium cycle in arterial smooth muscle. In: Calcium Blockers Mechanism of Action and Clinical Applications. ed. S.F. Flaim and R. Zelis. Urban and Scwarzenberg. Baltimore. pp. 53-63.

110. Allen Mangel, Cornelis van Breemen, Mohammad Fahim and Rodger Loutzenhiser (1983) Measurement of the in vivo mechanical activity and extracellular Ca-45 exchange in arterial smooth muscle. In: Vascular Neuroeffector Mechanisms: 4th International Symposium. ed. J. Bevan et.al. Raven Press. pp. 347-351.

111. Allen W. Mangel, Claudia P. Mangel and Kenton M. Sanders (1984) Modulation of intestinal electrical and mechanical activity by calcium. INSERM Symposia Series: Ca Regulations in Smooth Muscle. vol. 124: pp.111-118.

112. Richard A. Gillis, Wesley P. Norman, Dinkar K. Kasbekar, Allen W. Mangel, Lana Skirboll, John A. Quest and Frank D. Pagani (1987) Central nervous system control of gastrointestinal smooth muscle. In: Cellular Physiology and Clinical Studies of Gastrointestinal Smooth Muscle. ed. J. Szurszewski. Elsevier Science Publishers B.V. pp. 209-223.

113. A.W. Mangel, J.G. Fitz and I.L. Taylor (1991) Peptides do not induce contractions in gastrointestinal smooth muscle in calcium-free solution. Gen. Pharmacol. 22:1135-7.

114. Allen W. Mangel (1998) Regulation of cholecystokinin secretion by potassium and calcium channels. In: O.E.S.O.-The Esophagogastric Junction. Editors:Giuli, Galmiche, Jamieson, Scarpignato. John Libbey Eurotext, Paris, pp. 158-161.

115. A. Baxendale, C. Bountra, N. Clayton, D. Gunput, P.P.A. Humphrey, K. Kozlowski, A. Mangel and M. O’Sullivan (1999) Irritable bowel syndrome as visceral hyperalgesia: implications for therapy? Current Opinion in CPNS Investigational Drugs 1: 86-97.

116. W. Alderton, A. Angrll, N. Clayton, C. Craig, J. Dawson, A. Frend, J. McGill, A. Mangel, S. Moncada, D. Rees, L. Russell, S. Schwartz, N. Waslidge and R. Knowles (2000) GW274150 is a potent, long-acting, highly-selective inhibitor of inducible nitric oxide synthase (NOS-2) with therapeutic potential in post- operative ileus. In: The Biology of Nitric Oxide Part 7.ed: S. Moncada, L.E. Gustafsson, N.P. Wiklund, E.A. Higgs. Portland Press Ltd, London. pg. 22.

117. Allen W. Mangel, Sheri E. Fehnel, Stephanie R. Earnshaw and Tobin P. Mangel (2009) Pathways for the development of drugs to treat irritable bowel syndrome: from molecule identification through approval. In: Irritable Bowel Syndrome ed: J.D. Driggers and C.A. Pellegrino. Nova Science Publishers, New York. pp: 1-15.

118. A. Mangel and K. Lothman (2018) Emergence of a new paradigm in understanding the cardiovascular system: pulse synchronized contractions.

(Reprinted) Top 10 Contributions on Cardiology. Avid Sciences Publishers. 2-10.

Contact this candidate